Engaging with public policy stakeholders

Government bodies and public officials play an important role in society, for example by establishing and maintaining the necessary conditions and institutions for economic stability, social cohesion and environmental protection as well as for providing access to healthcare for their citizens. For all these reasons, Roche considers and respects public policy stakeholders as important partners.

We are convinced that proactively and responsibly engaging with public policy stakeholders is a fundamental aspect of good public governance. We seek to inform and work closely with government officials in order to highlight and address the issues that affect the healthcare industry and advance its regulatory framework.

As we focus on finding new medicines and diagnostics that help patients live longer, better lives and that evolve the practice of medicine, we believe that it is our responsibility to share relevant data and insights, as well as our perspective, to inform the public debate.

We strive to strengthens stakeholders’ understanding of—and trust in—our business, explaining what we do, how we do it and our contribution to society. We are convinced that this responsible and constructive form of lobbying is in the interest of all parties involved and of society as a whole.

Roche is committed to participating in a constructive, transparent, sincere and responsible dialogue with government officials by providing relevant, coherent, conclusive and honest information.

All employees working with government officials are expected to act in a legal and transparent way, complying with all applicable laws and regulations as well as with the standards set out in our Good Practice Guidelines on Working with Government Officials.

Currently, our two key issues of engagement are the following:

Access & Innovation

  • How to provide patient access to our medicines and diagnostics
  • How to create a culture which fosters innovation, e.g. by granting intellectual property (IP) protection
  • How to get a fair value for our innovative products, devices and services

Personalised Healthcare

  • How to develop innovative approaches to personalised healthcare
  • How to ensure access to big data

Supporting associations and political institutions

Roche remains independent of any political affiliation. Where appropriate, Roche discloses contributions to associations and political institutions publicly and signs up in transparency registers of public authorities. Further details related to Switzerland, the US and EU institutions are listed below.

We actively participate in public discussions through our engagement and contributions to trade and industry associations such as the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), Biotechnology Industry Organization (BIO), Pharmaceutical and Research Manufacturers of America (PhRMA), interpharma Switzerland, MedTech Europe and Advanced Medical Technology Association (AdvaMed). These groups represent the biopharmaceutical and diagnostics industry in the public debate and advocate public policies that support innovation and that will benefit patients, healthcare systems and society as a whole.

We believe it is important to engage with a broad range of external stakeholders to ensure diverse perspectives are considered. We partner with third party organisations to inform our policy positions and further our shared goal of advancing innovation and making a positive impact on society.